<DOC>
	<DOCNO>NCT01635504</DOCNO>
	<brief_summary>Altered contour low face frequent complication human immunodeficiency virus ( HIV ) . HIV facial lipoatrophy loss facial fat commonly result antiretroviral therapy . Posterior cheek enlargement lead bulky widen low facial contour also see HIV . These change lead significant cosmetic disfigurement enormous psychosocial impact patient . They also make individual vulnerable make recognizable person live HIV . Posterior cheek enlargement well characterize . Both parotid salivary gland masseter muscle locate posterior cheek region . Although parotid gland enlargement common complication HIV , unknown whether enlargement masseter muscle also contribute . The investigator plan study posterior cheek enlargement HIV positive individual . The investigator also plan use botulinum toxin A novel treatment improve alter low facial contour see HIV . This treatment already demonstrate efficacy HIV negative individual enlargement masseter muscle . Botulinum toxin also use safely salivary gland individual excessive drool result neurological disease . In trial HIV+ patient , investigator already demonstrate efficacy use botulinum toxin A treatment posterior cheek enlargement , result parotid masseter muscle enlargement . The investigator anticipate study increase understand posterior cheek enlargement HIV lead development novel treatment important complication . The investigator hypothesize posterior cheek enlargement HIV+ patient case result masseter muscle hypertrophy well parotid gland enlargement . The investigator also hypothesize treatment posterior cheek enlargement botulinum toxin A result aesthetically appeal lower facial contour HIV+ patient . This already demonstrate trial HIV+ patient , dramatic change volume masseter muscle parotid gland 12 week treatment botulinum toxin A .</brief_summary>
	<brief_title>HIV Posterior Cheek Enlargement</brief_title>
	<detailed_description>BACKGROUND AND SIGNIFICANCE Altered contour low face frequent complication HIV lead significant cosmetic disfigurement social stigmatization . However , posterior cheek enlargement HIV poorly characterize . The parotid masseter overlie mandibular ramus , thus contribute lower facial contour . Parotid hypertrophy recognize common complication HIV . It presently unknown whether masseter muscle hypertrophy also contribute cosmetic deformity . The investigator conduct prospective pilot study HIV+ patient determine whether masseter muscle hypertrophy parotid gland enlargement contribute bulky widen low facial contour , whether aesthetic appearance due primarily apparent muscle enlargement attributable facial lipoatrophy . Development novel treatment address HIV-associated cosmetic change increasingly important burden disease expand globally . There limited advance salivary gland surgery recent year . The benign nature parotid gland hypertrophy require surgeon preserve key anatomical structure important marker outcome . As , parotidectomy controversial procedure . Treatments masseter hypertrophy include surgical reduction masseter muscle resection mandibular angle create narrower facial width . These surgical treatment involve significant complication facial nerve injury , infection , scar , bleeding , swell trismus . This highlight need develop treatment posterior cheek enlargement . Botulinum toxin highly efficacious cost-effective , nonsurgical option reduce width improve shape low face jawline . Botulinum toxin masseter hypertrophy parotid enlargement HIV negative individual sialorrhea neurological disease safe effective treatment condition . However , study publish date use botulinum toxin set HIV . Furthermore , investigator already demonstrate efficacy use botulinum toxin A treatment posterior cheek enlargement trial HIV+ patient parotid enlargement masseter hypertrophy . This patient dramatic response clinically demonstrate 19.0 % 19.4 % mean reduction volume parotid gland masseter muscle , respectively , 12 week injection botulinum toxin A . He experience adverse effect injection . The investigator use clinical , photographic radiological evaluation determine efficacy durability botulinum toxin A alter low facial contour HIV+ patient . The investigator anticipate , minimum , study improve understand posterior cheek enlargement see HIV+ patient . The result study may translate novel evidence-based use botulinum toxin management alter low facial contour HIV+ patient . This could potentially improve psychosocial wellbeing patient afflict devastating disease . STUDY PROTOCOL This initial pilot study 5 participant . Participants posterior cheek enlargement photograph take baseline CT scan head perform . Botulinum toxin A injected identifying inferior border zygomatic arch mandibular ramus well anterior posterior demarcation posterior cheek enlargement . Injections perform percutaneously palpation . A total 10 U inject 5 evenly space point posterior cheek enlargement give total dose 50 U per side . Participants evaluate clinically 4 , 8 12 week injection , photograph , questionnaire assess patient satisfaction side effect . A CT scan head perform 12 week injection botulinum toxin A . Long-term efficacy botulinum toxin A evaluate 6 12 month post injection clinically , photographs questionnaire assess patient satisfaction side effect . The primary outcome change volume masseter muscle parotid gland 12 week treatment botulinum toxin A . The mean change standard deviation determine . A secondary outcome relative contribution masseter hypertrophy parotid enlargement posterior cheek enlargement HIV+ patient . The pre-treatment volume masseter muscle parotid gland determine HIV+ participant compare normal control publish literature .</detailed_description>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>1 . Aged 19 old 2 . Are HIV positive 3 . Have facial lipoatrophy clinically widen low facial contour 1 . Have previous facial injection product 2 . Have active infection face 3 . Are receive active treatment interferon systemic corticosteroid 4 . Are pregnant breastfeed 5 . Have know preexist renal disease 6 . Have poorly control diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>HIV lipoatrophy</keyword>
	<keyword>masseter hypertrophy</keyword>
	<keyword>parotid enlargement</keyword>
	<keyword>botulinum toxin</keyword>
</DOC>